MiMedx Group logo
MiMedx Group MDXG
$ 4.71 0.1%
report update icon

Quarterly report 2026-Q2
added 07-29-2026

MiMedx Group Cash Flow 2025-2009 | MDXG

Brief overview of MiMedx Group's cash movements

The comparison covers five available annual reports between 2021 and 2025.

Operating cash flow recovered from negative territory and reached $74 million. Core operations returned to generating cash.

Positive cash generation persisted in 3 of five years, so stability is not unconditional.

Operating cash flow covered cumulative profit by 1.35x, providing strong cash confirmation.

Cash from operations as a share of revenue increased from -0.8% to 17.7%, improving cash efficiency.

Working capital grew $42.2 million, or 10.1% of sales. Part of cash generation funded day-to-day operations.

What the cash flows show

MiMedx Group's cash flows are broadly resilient, though selected ratios need monitoring. Positive earnings conversion and moderate investment demand remain important.

Annual Cash Flow MiMedx Group

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Operating Cash Flow

74 M 66.2 M 26.8 M -17.9 M -1.98 M -30.3 M -39.4 M 35.8 M 62.9 M 23.8 M 18.8 M 16.8 M -284 K -3.33 M -6.66 M -8.16 M -

Depreciation & Amortization

14.9 M 6.04 M 3.43 M 3.34 M 4.36 M 5.78 M 6.55 M 5.88 M 4.09 M 3.33 M 1.8 M 1.2 M 637 K 465 K 447 K 444 K -

Accounts Payables

14.5 M 7.41 M 9.05 M 8.45 M 7.38 M 8.76 M - - - - - - - - - - -

Accounts Receivables

75.7 M 55.8 M 53.9 M 43.1 M 40.4 M 35.4 M 32.3 M 51 M 64.8 M 67.2 M 53.8 M 26.7 M 16.1 M 7.65 M 1.89 M 162 K -

Total Inventories

25.3 M 23.8 M 21 M 13.2 M 11.4 M 10.4 M 9.1 M 16 M - 17.8 M 7.46 M 5.13 M 3.88 M 3.02 M 713 K 112 K -

All numbers in USD currency

Quarterly Cash Flow MiMedx Group

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-8.14 M 1.88 M - 49 M - 5.3 M - - - 5.98 M - - - -4.05 M - -12.3 M - -10.2 M - 1.25 M - -6.68 M - -20 M -15.4 M -12.3 M - -16.3 M -13.1 M -15.3 M - 34.3 M 30.9 M 10.2 M - - - 10.6 M - 9.15 M 6.3 M -977 K - 14.5 M 7.14 M 4.21 M - 8.52 M -432 K -1.61 M - -1.12 M -2.85 M -2.1 M - -2.46 M -1.6 M -1.29 M - -5.01 M -3.92 M -1.79 M

Depreciation & Amortization

441 K 528 K - 572 K 558 K 558 K - 192 K 558 K 558 K - 190 K 191 K 714 K - 831 K 858 K 860 K - 923 K 1.31 M 1.16 M - 1.57 M 1.42 M 1.51 M - 1.64 M 1.6 M 1.7 M - 1.4 M 1.3 M 1.22 M - 1.01 M 1.12 M 946 K - 838 K 821 K 734 K - 470 K 422 K 354 K - 313 K 288 K 263 K - 185 K 139 K 98.8 K - 354 K 231 K 110 K - 331 K 232 K 116 K

Accounts Payables

8.29 M 11.5 M 14.5 M 11.4 M 8.5 M 8.87 M 7.41 M 6.92 M 7.6 M 9.7 M 9.05 M 9.17 M 8.15 M 7.82 M 8.85 M 8.82 M - 8.12 M 7.38 M 6.88 M 10.6 M 6.92 M 8.76 M 8.76 M 8.76 M 8.76 M 8.71 M 8.71 M 8.71 M 10.7 M 14.9 M - 14.9 M 14.9 M - 8.77 M 11.5 M 10.9 M 11.4 M 11.2 M 11.4 M 11.4 M 6.63 M 7.24 M 6.63 M 6.63 M 3.66 M 2.76 M 3.66 M 3.66 M 2.49 M 2.21 M 2.49 M 2.49 M 1.25 M - 1.25 M 1.25 M - - - -

Accounts Receivables

41.3 M 46 M 75.7 M 78.2 M 69.2 M 62.3 M 55.8 M 54 M 52.8 M 57 M 53.9 M 49 M 49 M 44.7 M 43.1 M 40.8 M - 37.7 M 40.4 M 36.5 M 37.2 M 35.4 M 35.4 M 35.4 M 35.4 M 35.4 M 32.3 M 32.3 M 32.3 M 32.3 M 51 M - - - 64.8 M 59.6 M 60.7 M 66.8 M 1.93 M 67.2 M 67.2 M 67.2 M 53.8 M 53.8 M 53.8 M 53.8 M 26.7 M 26.7 M 26.7 M 26.7 M 16.1 M 16.1 M 16.1 M 16.1 M 7.65 M 7.65 M 7.65 M 7.65 M 1.89 M 1.89 M 1.89 M 1.89 M

Total Inventories

20.9 M 26.2 M 25.3 M 26.5 M 24.9 M 24.1 M 23.8 M 24.2 M 25.1 M 24.5 M 21 M 19.1 M 16.8 M 14.7 M 13.2 M 14 M - 13.2 M 11.4 M 11.2 M 10.1 M 11.6 M 10.4 M 10.4 M 10.4 M 10.4 M 9.1 M 9.1 M 9.1 M 9.1 M 16 M - 16 M 16 M 9.47 M 10.4 M 15 M 16 M 15.9 M 17.8 M 17.8 M 17.8 M 7.46 M 7.46 M 7.46 M 7.46 M 5.13 M 5.13 M 5.13 M 5.13 M 3.88 M 3.88 M 3.88 M 3.88 M 3.02 M 3.02 M 3.02 M 3.02 M 713 K 713 K 713 K 713 K

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company MiMedx Group, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Medical devices sector

Issuer Price % 24h Market Cap Country
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 64.0 7.26 % $ 9.72 B usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 44.68 0.06 % $ 66.1 B usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.7 0.06 % $ 634 M israelIsrael
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.61 13.03 % $ 414 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 45.18 3.31 % $ 1.4 B usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 4.3 1.63 % $ 268 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 16.08 0.75 % $ 576 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Electromed Electromed
ELMD
$ 27.86 1.05 % $ 230 M usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 65.58 3.69 % $ 1.94 B costa-ricaCosta-rica
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 85.73 0.32 % $ 50.1 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 5.57 0.43 % $ 753 M usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 2.9 0.69 % $ 63.9 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 15.88 2.25 % $ 1.22 B usaUSA
Inogen Inogen
INGN
$ 5.23 2.75 % $ 139 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 14.19 0.21 % $ 917 M israelIsrael
Inspire Medical Systems Inspire Medical Systems
INSP
$ 68.81 0.59 % $ 2.02 B usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.63 2.51 % $ 10.7 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 85.2 0.08 % $ 1.08 B usaUSA
AxoGen AxoGen
AXGN
$ 43.32 0.48 % $ 1.99 B usaUSA
Align Technology Align Technology
ALGN
$ 145.63 4.36 % $ 10.6 B usaUSA
LENSAR LENSAR
LNSR
$ 7.08 0.28 % $ 84.7 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Medtronic PLC Medtronic PLC
MDT
$ 88.51 0.32 % $ 113 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Myomo Myomo
MYO
$ 1.67 1.83 % $ 69.9 M usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 0.66 0.45 % $ 42.8 M israelIsrael
InspireMD InspireMD
NSPR
$ 0.7 0.37 % $ 45 M israelIsrael
Orthofix Medical Orthofix Medical
OFIX
$ 9.16 0.11 % $ 363 M curacaoCuracao
Outset Medical Outset Medical
OM
$ 3.13 1.29 % $ 47.6 K usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 135.78 0.01 % $ 9.55 B usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 5.6 1.66 % $ 169 M canadaCanada
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.18 0.63 % $ 136 M usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
AVITA Medical AVITA Medical
RCEL
$ 11.58 5.75 % $ 323 M australiaAustralia
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.83 1.37 % $ 116 M usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 1.87 5.06 % $ 5.19 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.22 0.4 % $ 27 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 26.68 0.02 % $ 23.1 B britainBritain
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA